Inhibitory effect of KW-3635, a new thromboxane A2-receptor antagonist, on arterial thrombosis in guinea pigs.
The antithrombotic effects of the thromboxane (TX) A2-receptor antagonist and aspirin were determined using a photochemically-induced arterial thrombosis model in the femoral arteries of guinea pigs. KW-3635 (sodium (E)-11-[2-(5,6-dimethyl-1-benzimidazolyl)ethylidene]-6,11- dihydrodibenz[b,e]-oxepine-2-carboxylate monohydrate) and BM-13505, both of which are TXA2-receptor antagonists, and aspirin inhibited the thrombus formation at the doses that inhibited the ex vivo platelet aggregation induced by sodium arachidonate (100 microM) or collagen (3 micrograms/ml). These results support the notion that TXA2 is an important mediator in the present model of arterial thrombogenesis.
Higo
K
K
Department of Pharmacology, Pharmaceutical Research Laboratories, Kyowa Hakko Kogyo Co., Ltd., Shizuoka, Japan.
Karasawa
A
A
D000818:Animals; D016718:Arachidonic Acid / Q000494:pharmacology; D001241:Aspirin / Q000008:administration & dosage / Q000494:pharmacology; D001562:Benzimidazoles / Q000008:administration & dosage / Q000494:pharmacology*; D001584:Benzoxepins / Q000008:administration & dosage / Q000494:pharmacology*; D003094:Collagen / Q000494:pharmacology; D004195:Disease Models, Animal; D005263:Femoral Artery; D006168:Guinea Pigs; D008297:Male; D010648:Phenylacetates / Q000008:administration & dosage / Q000494:pharmacology; D010974:Platelet Aggregation / Q000187:drug effects*; D013449:Sulfonamides / Q000008:administration & dosage / Q000494:pharmacology; D013927:Thrombosis / Q000188:drug therapy*; D013928:Thromboxane A2 / Q000037:antagonists & inhibitors* / Q000502:physiology
D001562:Benzimidazoles; D001584:Benzoxepins; D010648:Phenylacetates; D013449:Sulfonamides; D016718:Arachidonic Acid; D013928:Thromboxane A2; D003094:Collagen; D001241:Aspirin; C051762:daltroban; C065729:KW 3635